| Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer DJ Sargent, S Marsoni, G Monges, SN Thibodeau, R Labianca, ... Journal of clinical oncology 28 (20), 3219, 2010 | 1775 | 2010 |
| Randomized trial of TAS-102 for refractory metastatic colorectal cancer RJ Mayer, E Van Cutsem, A Falcone, T Yoshino, R Garcia-Carbonero, ... New England Journal of Medicine 372 (20), 1909-1919, 2015 | 1395 | 2015 |
| Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial C Louvet, R Labianca, P Hammel, G Lledo, MG Zampino, T André, ... Journal of Clinical Oncology 23 (15), 3509-3516, 2005 | 1257 | 2005 |
| FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular … C Cremolini, F Loupakis, C Antoniotti, C Lupi, E Sensi, S Lonardi, S Mezi, ... The Lancet Oncology 16 (13), 1306-1315, 2015 | 1124 | 2015 |
| Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer F Loupakis, C Cremolini, G Masi, S Lonardi, V Zagonel, L Salvatore, ... New England Journal of Medicine 371 (17), 1609-1618, 2014 | 1108 | 2014 |
| Impact of follow-up testing on survival and health-related quality of life in breast cancer patients: a multicenter randomized controlled trial P Ghezzi, S Magnanini, M Rinaldini, F Berardi, G Di Biagio, F Testare, ... Jama 271 (20), 1587-1592, 1994 | 570 | 1994 |
| Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: a phase II multicentric study E Diaz-Rubio, J Sastre, A Zaniboni, R Labianca, H Cortes-Funes, ... Annals of Oncology 9 (1), 105-108, 1998 | 308 | 1998 |
| Nonmyeloablative conditioning followed by hematopoietic cell allografting and donor lymphocyte infusions for patients with metastatic renal and breast cancer M Bregni, A Dodero, J Peccatori, A Pescarollo, M Bernardi, I Sassi, ... Blood, The Journal of the American Society of Hematology 99 (11), 4234-4236, 2002 | 265 | 2002 |
| Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with … C Cremolini, C Antoniotti, D Rossini, S Lonardi, F Loupakis, F Pietrantonio, ... The Lancet Oncology 21 (4), 497-507, 2020 | 255 | 2020 |
| Association of obesity with survival outcomes in patients with cancer: a systematic review and meta-analysis F Petrelli, A Cortellini, A Indini, G Tomasello, M Ghidini, O Nigro, M Salati, ... JAMA Network Open 4 (3), e213520-e213520, 2021 | 250 | 2021 |
| Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results … C Cremolini, F Loupakis, C Antoniotti, S Lonardi, G Masi, L Salvatore, ... Annals of oncology 26 (6), 1188-1194, 2015 | 189 | 2015 |
| Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trial S Cascinu, R Berardi, R Labianca, S Siena, A Falcone, E Aitini, S Barni, ... The lancet oncology 9 (1), 39-44, 2008 | 175 | 2008 |
| Nuclear factor-kB tumor expression predicts response and survival in irinotecan-refractory metastatic colorectal cancer treated with cetuximab-irinotecan therapy M Scartozzi, I Bearzi, C Pierantoni, A Mandolesi, F Loupakis, A Zaniboni, ... Journal of clinical oncology 25 (25), 3930-3935, 2007 | 155 | 2007 |
| Intermittent versus continuous chemotherapy in advanced colorectal cancer: a randomised ‘GISCAD’trial R Labianca, A Sobrero, L Isa, E Cortesi, S Barni, D Nicolella, M Aglietta, ... Annals of oncology 22 (5), 1236-1242, 2011 | 150 | 2011 |
| Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study E Van Cutsem, C Boni, J Tabernero, B Massuti, G Middleton, F Dane, ... Annals of Oncology 26 (1), 149-156, 2015 | 144 | 2015 |
| The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first … G Fucà, V Guarini, C Antoniotti, F Morano, R Moretto, S Corallo, ... British journal of cancer 123 (3), 403-409, 2020 | 141 | 2020 |
| A randomized trial of intensive versus minimal surveillance of patients with resected Dukes B2-C colorectal carcinoma G Rosati, G Ambrosini, S Barni, B Andreoni, G Corradini, G Luchena, ... Annals of oncology 27 (2), 274-280, 2016 | 135 | 2016 |
| Intensive weekly chemotherapy for advanced gastric cancer using fluorouracil, cisplatin, epi-doxorubicin, 6S-leucovorin, glutathione, and filgrastim: a report from the Italian … S Cascinu, R Labianca, P Alessandroni, M Marcellini, RR Silva, ... Journal of clinical oncology 15 (11), 3313-3319, 1997 | 131 | 1997 |
| Oxaliplatin in combination with 5-fluorouracil (5-FU) and leucovorin (LV) in patients with metastatic gastric cancer (MGC) L Cavanna, F Artioli, C Codignola, A Lazzaro, A Rizzi, A Gamboni, L Rota, ... American journal of clinical oncology 29 (4), 371-375, 2006 | 130 | 2006 |
| Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset H Blons, JF Emile, K Le Malicot, C Julié, A Zaanan, J Tabernero, E Mini, ... Annals of oncology 25 (12), 2378-2385, 2014 | 129 | 2014 |
